The Global Mid-Market Specialist
Zurich– On 26 January 2017 Actelion announced that Johnson & Johnson has offered to acquire 100% of the outstanding share capital of Actelion at a price of US$280 per ordinary share. The intended offer values Actelion’s total outstanding share capital at around US$30 billion.
As part of the transaction, immediately prior to the completion of the acquisition, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company. The shares of the new company, which will be listed on the SIX Swiss Exchange, will be distributed to Actelion’s shareholders as a stock dividend upon closing of the tender. Johnson & Johnson will initially hold 16% of the shares and have rights to an additional 16% the new company’s equity through a convertible note.
Alantra provided a fairness opinion to Actelion’s board of directors in order to assess the financial adequacy of the public tender offer of Johnson & Johnson.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. To go to Actelion’s press release, please click here.
We use our own and third-party cookies to improve our services and show you advertising related to your preferences by analyzing your browsing habits. If you go on surfing, we will consider you accepting its use. You can change the settings or get more information here.